Lasa Supergenerics shutdown persists after uninsured fire

Lasa Supergenerics Limited said its production shutdown continued through the quarter ended September 30, 2026, reporting revenue from operations of Rs 1.24 lakh after the May 18, 2025 fire at its mother unit. The uninsured incident previously resulted in an exceptional loss of Rs 20.57 crore, while damage remains unquantified.

Why has Lasa Supergenerics not restarted production?

Lasa Supergenerics has not restarted production because the May 18, 2025 fire damaged inventory, property, plant and equipment, office space and operations at its Plot No. C-4 mother unit in Lote Parshuram Industrial Area, Ratnagiri. The company said this unit was central to its primary production activities and that all production processes came to a halt after the incident.

The disruption covers the company’s other owned and leased facilities because they depended on output from the C-4 unit for further processing and production. Lasa Supergenerics said activities at all subsequent units had ceased, and it has informed stock exchanges, the Factory Inspector and the Office of the Labor Commissioner about the suspension of operations.

Access to the site remains an obstacle to assessing the fire’s effects. Lasa Supergenerics said financial constraints and the non-operational factory meant certain workers had not received salaries or wages, followed by a strike and protest by an unrecognised labour union. The company said the protest obstructed entry and exit, and that valuers, chartered engineers and technical experts were reluctant to enter the premises.

Lasa Supergenerics has filed a police complaint seeking assistance and protection, but said it had been unable to gain proper access because of a lack of effective intervention by authorities. Management’s preliminary view is that a substantial part of plant and machinery was severely damaged or destroyed, but it cannot quantify the final loss without physical inspection and a technical evaluation.

How did Lasa Supergenerics’ quarterly financial results change?

Lasa Supergenerics reported revenue from operations of Rs 1.24 lakh for the quarter ended September 30, 2026, compared with Rs 1.23 crore in the preceding June 2026 quarter and Rs 3.06 crore in the September 2025 quarter. Total income was Rs 1.55 lakh, against Rs 1.33 crore sequentially and Rs 3.07 crore a year earlier, reflecting the continuing production stoppage.

The net loss after tax narrowed to Rs 1.84 crore in the September 2026 quarter from Rs 3.58 crore in June 2026 and Rs 6.25 crore in September 2025. Total expenses declined to Rs 1.81 crore from Rs 4.32 crore in the preceding quarter and Rs 8.75 crore a year earlier, while depreciation and amortisation was broadly unchanged at Rs 1.57 crore.

For the half year ended September 30, 2026, revenue from operations was Rs 1.24 crore, compared with Rs 23.07 crore in the corresponding 2025 period. The half-year net loss was Rs 5.42 crore, narrower than Rs 27.37 crore a year earlier. Lasa Supergenerics has one business segment, active pharmaceutical ingredients, or API, and therefore did not report a segmental revenue split.

What financial effects of the fire has Lasa Supergenerics disclosed?

Lasa Supergenerics recognised an exceptional loss of Rs 20.57 crore in earlier periods because assets affected by the May 2025 fire were not insured. The company said the reported loss does not resolve the final damage assessment: it cannot establish the exact extent of the damage until detailed inspection and technical evaluation can take place.

Property, plant and equipment stood at Rs 36.63 crore as at September 30, 2026, down from Rs 39.70 crore a year earlier, while intangible assets declined to Rs 15.06 crore from Rs 18.28 crore. Inventory was nil at September 30, 2026, compared with Rs 4.18 crore at September 30, 2025. The filing does not assign each balance-sheet movement to a particular cause.

Other equity was negative Rs 5.90 crore at September 30, 2026, compared with positive Rs 6.24 crore a year earlier, while current borrowings increased to Rs 9.69 crore from Rs 7.34 crore. Cash and cash equivalents were Rs 25.20 lakh, compared with Rs 28.83 lakh a year earlier, and operating activities used Rs 10.05 lakh of cash in the half year ended September 30, 2026.

What recovery options is Lasa Supergenerics considering?

Lasa Supergenerics said management is exploring contract manufacturing arrangements and/or leasing its facility, subject to regulatory approvals and consents. Management said it could not commence manufacturing at its facilities because of pending statutory clearances and operational constraints, and it did not disclose a restart date, manufacturing partner or lease agreement.

The company is also evaluating a recovery and rebuilding strategy that could include funding arrangements to restore operations. This is an evaluation rather than a disclosed financing commitment, amount or timetable. Any recovery route must operate alongside the need for access to the C-4 premises and a completed technical assessment of fire damage.

Lasa Supergenerics has stopped recognising government grant income on an accrual basis following the suspension of production. Management said the shutdown created uncertainty over fulfilment of grant conditions for future periods, so recognition will remain discontinued pending restoration of operations and reassessment of compliance.

The filing also discloses Goods and Services Tax, or GST, notices and demand orders totalling Rs 38.11 crore across various assessment periods. Lasa Supergenerics has filed appeals or other responses and is contesting the matters on legal advice. Management believes it has a case on merits and has made no provision, treating the amount as a contingent liability excluding unascertainable interest and penalties.

Conclusion

Lasa Supergenerics remains unable to operate its API business more than 16 months after the May 2025 fire, with September-quarter revenue of Rs 1.24 lakh. The uninsured Rs 20.57 crore exceptional loss, shutdown of dependent units, restricted site access and unquantified physical damage show the extent of the unresolved operational disruption.

The next developments to watch are access for technical assessment, regulatory approvals for contract manufacturing or leasing, and any funding arrangement for rebuilding. Management has not provided a production-restart target, while the Rs 38.11 crore GST matters and the reassessment of government-grant conditions remain unresolved.